CINP Clinical Trials

Advancing Treatment

CINP-203 is a randomized, phase 2 clinical trial that will be evaluating the safety and effectiveness of Halneuron (HAL) vs placebo in people with established neuropathy due to their chemotherapy. Participants will complete laboratory exams (blood work) and questionnaires to evaluate eligibility, safety, and quality of life. If eligible, participants will receive 8 doses of HAL or placebo over 14 days and will be followed for 28 days for safety and effectiveness. CINP-203 will enroll up to 200 people who have Chemotherapy Induced Neuropathic Pain (CINP) due to a Platinum or Taxane based chemotherapy regimen. Participants may be assigned to either an active treatment arm or the placebo control arm of the trial.

CINP-203 will be enrolled at multiple sites based in the United States.